Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions

[Display omitted] The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone–vinyl aceta...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 540; no. 1-2; pp. 171 - 177
Main Authors Sakai, Toshiro, Hirai, Daiki, Kimura, Shin-ichiro, Iwao, Yasunori, Itai, Shigeru
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 05.04.2018
Subjects
Online AccessGet full text

Cover

Loading…
Abstract [Display omitted] The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone–vinyl acetate copolymer (PVPVA) or polyvinylpyrrolidone (PVP) at a weight ratio of 1:1 or 1:2 using a melt extrusion technique. Tablets were prepared by conventional direct compression followed by pan coating. A mathematical model based on the Noyes–Whitney equation assuming that stable crystals precipitated at the changeable surface area of the solid–liquid interface used to estimate drug dissolution kinetics in a non-sink dissolution condition. All the ASD particles showed a maximum dissolution concentration approximately ten times higher than that of the crystalline drug. The ASD particles with PVPVA showed higher precipitation rate with lower polymer ratio, while PVP did not precipitate within 960 min regardless of the polymer ratio, suggesting the ASD particles of 1:1 drug:PVPVA (ASD-1) were the most unstable among the ASD particles considered. The dissolution of a core tablet with ASD-1 showed less supersaturation and a much higher precipitation rate than those of ASD-1 particles. However, a film-coated tablet or core tablet with a trace amount of hydroxypropylmethylcellulose (HPMC) showed a similar dissolution profile to that of the ASD-1 particles, indicating HPMC had a remarkable precipitation inhibition effect. Overall, these results suggest that tablet preparation with ASD may adversely affect the maintenance of supersaturation; however, this effect can be mitigated by adding an appropriate precipitation inhibitor to the formulation.
AbstractList The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone-vinyl acetate copolymer (PVPVA) or polyvinylpyrrolidone (PVP) at a weight ratio of 1:1 or 1:2 using a melt extrusion technique. Tablets were prepared by conventional direct compression followed by pan coating. A mathematical model based on the Noyes-Whitney equation assuming that stable crystals precipitated at the changeable surface area of the solid-liquid interface used to estimate drug dissolution kinetics in a non-sink dissolution condition. All the ASD particles showed a maximum dissolution concentration approximately ten times higher than that of the crystalline drug. The ASD particles with PVPVA showed higher precipitation rate with lower polymer ratio, while PVP did not precipitate within 960 min regardless of the polymer ratio, suggesting the ASD particles of 1:1 drug:PVPVA (ASD-1) were the most unstable among the ASD particles considered. The dissolution of a core tablet with ASD-1 showed less supersaturation and a much higher precipitation rate than those of ASD-1 particles. However, a film-coated tablet or core tablet with a trace amount of hydroxypropylmethylcellulose (HPMC) showed a similar dissolution profile to that of the ASD-1 particles, indicating HPMC had a remarkable precipitation inhibition effect. Overall, these results suggest that tablet preparation with ASD may adversely affect the maintenance of supersaturation; however, this effect can be mitigated by adding an appropriate precipitation inhibitor to the formulation.
[Display omitted] The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water solubility and hydrophilic polymers were investigated. ASD particles were prepared with a drug and vinylpyrrolidone–vinyl acetate copolymer (PVPVA) or polyvinylpyrrolidone (PVP) at a weight ratio of 1:1 or 1:2 using a melt extrusion technique. Tablets were prepared by conventional direct compression followed by pan coating. A mathematical model based on the Noyes–Whitney equation assuming that stable crystals precipitated at the changeable surface area of the solid–liquid interface used to estimate drug dissolution kinetics in a non-sink dissolution condition. All the ASD particles showed a maximum dissolution concentration approximately ten times higher than that of the crystalline drug. The ASD particles with PVPVA showed higher precipitation rate with lower polymer ratio, while PVP did not precipitate within 960 min regardless of the polymer ratio, suggesting the ASD particles of 1:1 drug:PVPVA (ASD-1) were the most unstable among the ASD particles considered. The dissolution of a core tablet with ASD-1 showed less supersaturation and a much higher precipitation rate than those of ASD-1 particles. However, a film-coated tablet or core tablet with a trace amount of hydroxypropylmethylcellulose (HPMC) showed a similar dissolution profile to that of the ASD-1 particles, indicating HPMC had a remarkable precipitation inhibition effect. Overall, these results suggest that tablet preparation with ASD may adversely affect the maintenance of supersaturation; however, this effect can be mitigated by adding an appropriate precipitation inhibitor to the formulation.
Author Iwao, Yasunori
Kimura, Shin-ichiro
Sakai, Toshiro
Itai, Shigeru
Hirai, Daiki
Author_xml – sequence: 1
  givenname: Toshiro
  surname: Sakai
  fullname: Sakai, Toshiro
  organization: Pharmaceutical Research and Technology Labs. US, Astellas US Technology Inc., 1 Astellas Way, Northbrook, 60062 Illinois, United States
– sequence: 2
  givenname: Daiki
  surname: Hirai
  fullname: Hirai, Daiki
  organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
– sequence: 3
  givenname: Shin-ichiro
  surname: Kimura
  fullname: Kimura, Shin-ichiro
  organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
– sequence: 4
  givenname: Yasunori
  surname: Iwao
  fullname: Iwao, Yasunori
  organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
– sequence: 5
  givenname: Shigeru
  orcidid: 0000-0003-4035-3591
  surname: Itai
  fullname: Itai, Shigeru
  email: s-itai@u-shizuoka-ken.ac.jp
  organization: Department of Pharmaceutical Engineering, Graduate School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29447848$$D View this record in MEDLINE/PubMed
BookMark eNqFkU9v1DAQxS1URLd_PgLIRy4bxnESZ08IVaUgVeICZ8uxx6xXSRxspxJnvjiz3S1XTj6892b8fnPFLuY4I2NvBVQCRPfhUIXDsjdpqmoQfQV1BUK-YhvRK7mVjeou2Aak6retUPKSXeV8AICuFvINu6x3TaP6pt-wP_feoy2ZR8-LGUYs3Mc0raMpIc7czI7ndcj4a8WZpDBO3EbS5p-c5LJHkhdM2ZQ1mYKOu5BzHNfn9IB78xRiOg43U0zLPq6Zkxyefccc2fINe-3NmPH2_F6zH5_vv9992T5-e_h69-lxa2XXFioC0hsnnOmph9zBzrUopG0aITvsdnVjBxDgGwWDrxVap8CKDltlZCs7I6_Z-9PcJUXqk4ueQrY4jmZG-piuASQho2VkbU9Wm2LOCb1eUphM-q0F6CN_fdBn_vrIX0OtiT_l3p1XrMOE7l_qBTgZPp4MSEWfAiadbcDZoguJ7qBdDP9Z8RfkK55F
CitedBy_id crossref_primary_10_1016_j_ejps_2020_105682
crossref_primary_10_1016_j_ijpharm_2020_119504
crossref_primary_10_1007_s40005_023_00652_9
crossref_primary_10_1016_j_ijpharm_2022_122524
crossref_primary_10_1208_s12249_021_01986_z
crossref_primary_10_1016_j_ijpharm_2018_08_012
crossref_primary_10_1016_j_ijpharm_2019_01_009
crossref_primary_10_1208_s12249_020_01909_4
crossref_primary_10_1016_j_ijpharm_2022_122110
crossref_primary_10_1080_03639045_2018_1562467
crossref_primary_10_1016_j_ejps_2019_02_005
crossref_primary_10_1016_j_ijbiomac_2023_124825
crossref_primary_10_1016_j_lwt_2020_109556
crossref_primary_10_1016_j_ijpharm_2022_121881
crossref_primary_10_3390_pharmaceutics13071034
crossref_primary_10_3390_pharmaceutics13050731
crossref_primary_10_1016_j_ijpx_2024_100259
Cites_doi 10.1016/S0169-409X(96)00423-1
10.1016/j.ijpharm.2013.05.013
10.1016/j.ijpharm.2017.02.050
10.1002/jps.20906
10.1002/jps.21903
10.1016/j.ijpharm.2011.05.055
10.1016/S0939-6411(02)00061-9
10.1016/j.powtec.2015.08.047
10.1016/j.ijpharm.2003.07.010
10.1021/mp1003493
10.1016/j.ijpharm.2005.05.017
10.1021/mp500711c
10.1016/S0939-6411(00)00076-X
10.1016/j.ejpb.2013.09.007
10.1208/pt070368
10.1248/cpb.60.459
10.1021/js980403l
10.1016/S1056-8719(00)00107-6
10.1016/S0378-5173(97)00274-3
10.1016/j.ddtec.2011.10.002
10.1016/j.ejpb.2016.09.011
10.1248/cpb.52.244
10.1021/mp500480y
10.1016/j.ijpharm.2013.01.067
10.3109/10837450.2010.535826
10.1016/j.ijpharm.2011.08.032
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.ijpharm.2018.02.013
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-3476
EndPage 177
ExternalDocumentID 10_1016_j_ijpharm_2018_02_013
29447848
S0378517318300942
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
5GY
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AATCM
AAXUO
ABFNM
ABFRF
ABJNI
ABMAC
ABOCM
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPCBC
SSP
SSZ
T5K
TEORI
~02
~G-
AAQFI
AAXKI
AKRWK
NPM
.GJ
29J
3O-
53G
5VS
AAQXK
AAYXX
ABXDB
ADMUD
AFJKZ
ASPBG
AVWKF
AZFZN
CITATION
FEDTE
FGOYB
G-2
HMT
HVGLF
HZ~
R2-
SEW
SPT
WUQ
ZXP
7X8
ID FETCH-LOGICAL-c365t-5103fad1da80623909d5e13c44136e6924cb010f470bf27ecd70c16e57a3536a3
IEDL.DBID .~1
ISSN 0378-5173
IngestDate Sun Sep 29 07:15:43 EDT 2024
Thu Sep 26 16:34:40 EDT 2024
Wed Oct 16 00:59:21 EDT 2024
Fri Feb 23 02:29:54 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1-2
Keywords Amorphous solid dispersion
Solid–liquid interface
Polyvinylpyrrolidone
Dissolution model
Copovidone
Melt extrusion
Language English
License Copyright © 2018 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c365t-5103fad1da80623909d5e13c44136e6924cb010f470bf27ecd70c16e57a3536a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4035-3591
PMID 29447848
PQID 2003037365
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_2003037365
crossref_primary_10_1016_j_ijpharm_2018_02_013
pubmed_primary_29447848
elsevier_sciencedirect_doi_10_1016_j_ijpharm_2018_02_013
PublicationCentury 2000
PublicationDate 2018-04-05
PublicationDateYYYYMMDD 2018-04-05
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-04-05
  day: 05
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle International journal of pharmaceutics
PublicationTitleAlternate Int J Pharm
PublicationYear 2018
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Jahangiri, Barzegar-jalali, Garjani, Javadzadeh, Hamishehkar (b9000) 2015; 286
Ku, Dulin (b0060) 2012; 17
Serajuddln (b0105) 1999; 88
Wlodarski, Tajber, Sawicki (b0135) 2016; 109
Sun, Lee (b0110) 2015; 12
Teja, Patil, Shete, Patel, Bansal (b0115) 2013; 4
Chaulang, Patil, Ghodke, Khan, Yeole (b0015) 2008; 1
Van Den Mooter (b0125) 2012; 9
Kawabata, Wada, Nakatani, Yamada, Onoue (b0045) 2011; 420
Won, Kim, Lee, Park, Hwang (b0140) 2005; 301
Okimoto, Miyake, Ibuki, Yasumura (b0095) 1997; 159
Lipinski, Franc, Feeney (b0070) 1997; 23
Leuner, Dressman (b0065) 2000; 50
Lipinski (b0080) 2000; 44
Yamashita, Nakate, Okimoto, Ohike (b0150) 2003; 267
Hirasawa, Ishise, Miyata, Danjo (b0040) 2004; 52
Murdande, Pikal, Shanker, Bogner (b0090) 2010; 99
Modi, Tayade (b0085) 2006; 7
Han, Lee, Lee (b0030) 2011; 415
Vo, Park, Lee (b0130) 2013; 85
Guzman, Tawa, Zhang, Ratanabanangkoon, Shaw, Gardner, Chen, Moreau, Almarsson, Remenar (b0025) 2007; 96
Thommes, Ely, Carvajal, Pinal (b0120) 2011
Gardner, Walsh, Almarsson (b0020) 2004; 3
Sakurai, Sakai, Sako, Maitani (b0100) 2012; 60
Keen, Hughey, Bennett, Jannin, Rosiaux, Marchaud, Mcginity (b0050) 2015; 12
Kim, Kim, Cho, Cha, Park, Park, Hwang (b0055) 2013; 445
Hirai, Iwao, Kimura, Noguchi, Itai (b0035) 2017; 522
Lipinski (b0075) 2002; 5
Arunprasad, Narayanan, Rajalakshmi (b0005) 2010; 3
Breitenbach (b0010) 2002; 54
Xu, Dai (b0145) 2013; 453
Van Den Mooter (10.1016/j.ijpharm.2018.02.013_b0125) 2012; 9
Vo (10.1016/j.ijpharm.2018.02.013_b0130) 2013; 85
Chaulang (10.1016/j.ijpharm.2018.02.013_b0015) 2008; 1
Okimoto (10.1016/j.ijpharm.2018.02.013_b0095) 1997; 159
Lipinski (10.1016/j.ijpharm.2018.02.013_b0075) 2002; 5
Guzman (10.1016/j.ijpharm.2018.02.013_b0025) 2007; 96
Yamashita (10.1016/j.ijpharm.2018.02.013_b0150) 2003; 267
Sakurai (10.1016/j.ijpharm.2018.02.013_b0100) 2012; 60
Wlodarski (10.1016/j.ijpharm.2018.02.013_b0135) 2016; 109
Kawabata (10.1016/j.ijpharm.2018.02.013_b0045) 2011; 420
Teja (10.1016/j.ijpharm.2018.02.013_b0115) 2013; 4
Breitenbach (10.1016/j.ijpharm.2018.02.013_b0010) 2002; 54
Arunprasad (10.1016/j.ijpharm.2018.02.013_b0005) 2010; 3
Jahangiri (10.1016/j.ijpharm.2018.02.013_b9000) 2015; 286
Won (10.1016/j.ijpharm.2018.02.013_b0140) 2005; 301
Lipinski (10.1016/j.ijpharm.2018.02.013_b0070) 1997; 23
Xu (10.1016/j.ijpharm.2018.02.013_b0145) 2013; 453
Modi (10.1016/j.ijpharm.2018.02.013_b0085) 2006; 7
Hirasawa (10.1016/j.ijpharm.2018.02.013_b0040) 2004; 52
Keen (10.1016/j.ijpharm.2018.02.013_b0050) 2015; 12
Hirai (10.1016/j.ijpharm.2018.02.013_b0035) 2017; 522
Murdande (10.1016/j.ijpharm.2018.02.013_b0090) 2010; 99
Thommes (10.1016/j.ijpharm.2018.02.013_b0120) 2011
Serajuddln (10.1016/j.ijpharm.2018.02.013_b0105) 1999; 88
Han (10.1016/j.ijpharm.2018.02.013_b0030) 2011; 415
Leuner (10.1016/j.ijpharm.2018.02.013_b0065) 2000; 50
Lipinski (10.1016/j.ijpharm.2018.02.013_b0080) 2000; 44
Kim (10.1016/j.ijpharm.2018.02.013_b0055) 2013; 445
Ku (10.1016/j.ijpharm.2018.02.013_b0060) 2012; 17
Sun (10.1016/j.ijpharm.2018.02.013_b0110) 2015; 12
Gardner (10.1016/j.ijpharm.2018.02.013_b0020) 2004; 3
References_xml – volume: 415
  start-page: 89
  year: 2011
  end-page: 94
  ident: b0030
  article-title: Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Lee
– volume: 301
  start-page: 199
  year: 2005
  end-page: 208
  ident: b0140
  article-title: Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Hwang
– volume: 17
  start-page: 285
  year: 2012
  end-page: 302
  ident: b0060
  article-title: A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept
  publication-title: Pharm. Dev. Technol.
  contributor:
    fullname: Dulin
– volume: 85
  start-page: 799
  year: 2013
  end-page: 813
  ident: b0130
  article-title: Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs
  publication-title: Eur. J. Pharm. Biopharm.
  contributor:
    fullname: Lee
– volume: 23
  start-page: 3
  year: 1997
  end-page: 25
  ident: b0070
  article-title: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
  publication-title: Adv. Drug Deliv. Rev.
  contributor:
    fullname: Feeney
– volume: 99
  start-page: 1254
  year: 2010
  end-page: 1264
  ident: b0090
  article-title: Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis
  publication-title: J. Pharm. Sci.
  contributor:
    fullname: Bogner
– volume: 54
  start-page: 107
  year: 2002
  end-page: 117
  ident: b0010
  article-title: Melt extrusion: from process to drug delivery technology
  publication-title: Eur. J. Pharm. Biopharm.
  contributor:
    fullname: Breitenbach
– volume: 445
  start-page: 108
  year: 2013
  end-page: 116
  ident: b0055
  article-title: Supersaturatable formulations for the enhanced oral absorption of sirolimus
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Hwang
– start-page: 727
  year: 2011
  end-page: 735
  ident: b0120
  article-title: Improvement of the dissolution rate of poorly soluble drugs by solid crystal suspensions
  publication-title: Mol. Pharm.
  contributor:
    fullname: Pinal
– volume: 109
  start-page: 14
  year: 2016
  end-page: 23
  ident: b0135
  article-title: Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA
  publication-title: Eur. J. Pharm. Biopharm.
  contributor:
    fullname: Sawicki
– volume: 522
  start-page: 58
  year: 2017
  end-page: 65
  ident: b0035
  article-title: Mathematical model to analyze the dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid interface reaction
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Itai
– volume: 88
  start-page: 1058
  year: 1999
  end-page: 1066
  ident: b0105
  article-title: Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs
  publication-title: J. Pharm. Sci.
  contributor:
    fullname: Serajuddln
– volume: 286
  start-page: 538
  year: 2015
  end-page: 545
  ident: b9000
  article-title: Pharmacological and histological examination of atorvastatin-PVP K30 solid dispersions
  publication-title: Powder Technol.
  contributor:
    fullname: Hamishehkar
– volume: 420
  start-page: 1
  year: 2011
  end-page: 10
  ident: b0045
  article-title: Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system : Basic approaches and practical applications
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Onoue
– volume: 4
  start-page: 70
  year: 2013
  end-page: 94
  ident: b0115
  article-title: Drug-excipient behavior in polymeric amorphous solid dispersions
  publication-title: J. Excipients Food Chem.
  contributor:
    fullname: Bansal
– volume: 52
  start-page: 244
  year: 2004
  end-page: 247
  ident: b0040
  article-title: Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers
  publication-title: Chem. Pharm. Bull.
  contributor:
    fullname: Danjo
– volume: 1
  start-page: 386
  year: 2008
  end-page: 389
  ident: b0015
  article-title: Preparation and characterization of solid dispersion tablet of furosemide with crospovidone
  publication-title: J. Pharm. Tech.
  contributor:
    fullname: Yeole
– volume: 12
  start-page: 120
  year: 2015
  end-page: 126
  ident: b0050
  article-title: Eff ect of tablet structure on controlled release from supersaturating solid dispersions containing glyceryl behenate
  publication-title: Mol. Pharm.
  contributor:
    fullname: Mcginity
– volume: 453
  start-page: 36
  year: 2013
  end-page: 43
  ident: b0145
  article-title: Drug precipitation inhibitors in supersaturable formulations
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Dai
– volume: 7
  start-page: 1
  year: 2006
  end-page: 6
  ident: b0085
  article-title: Enhancement of dissolution profile by solid dispersion (kneading) technique
  publication-title: AAPS PharmSciTech
  contributor:
    fullname: Tayade
– volume: 60
  start-page: 459
  year: 2012
  end-page: 464
  ident: b0100
  article-title: Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug : physicochemical characterization and in vivo study
  publication-title: Chem. Pharm. Bull.
  contributor:
    fullname: Maitani
– volume: 3
  start-page: 130
  year: 2010
  end-page: 134
  ident: b0005
  article-title: Preparation and evaluation of solid dispersion of terbinafine hydrochloride
  publication-title: Int. J. Pharm. Sci. Rev. Res.
  contributor:
    fullname: Rajalakshmi
– volume: 159
  start-page: 85
  year: 1997
  end-page: 93
  ident: b0095
  article-title: Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Yasumura
– volume: 44
  start-page: 235
  year: 2000
  end-page: 249
  ident: b0080
  article-title: Drug-like properties and the causes of poor solubility and poor permeability
  publication-title: J. Pharamacol. Toxicol. Methods
  contributor:
    fullname: Lipinski
– volume: 96
  start-page: 2686
  year: 2007
  end-page: 2702
  ident: b0025
  article-title: Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations
  publication-title: J. Pharm. Sci.
  contributor:
    fullname: Remenar
– volume: 3
  start-page: 926
  year: 2004
  end-page: 934
  ident: b0020
  article-title: Drugs as materials: valuing physical form in drug discovery
  publication-title: Nat. Rev.
  contributor:
    fullname: Almarsson
– volume: 12
  start-page: 1203
  year: 2015
  end-page: 1215
  ident: b0110
  article-title: Evolution of supersaturation of amorphous pharmaceuticals: Nonlinear rate of supersaturation generation regulated by matrix diffusion
  publication-title: Mol. Pharm.
  contributor:
    fullname: Lee
– volume: 5
  start-page: 82
  year: 2002
  end-page: 85
  ident: b0075
  article-title: Poor aqueous solubility – an industry wide problem in drug discovery
  publication-title: Am. Pharm. Rev.
  contributor:
    fullname: Lipinski
– volume: 9
  start-page: e79
  year: 2012
  end-page: e85
  ident: b0125
  article-title: The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate
  publication-title: Drug Discov. Today Technol.
  contributor:
    fullname: Van Den Mooter
– volume: 50
  start-page: 47
  year: 2000
  end-page: 60
  ident: b0065
  article-title: Improving drug solubility for oral delivery using solid dispersions
  publication-title: Eur. J. Pharm. Biopharm.
  contributor:
    fullname: Dressman
– volume: 267
  start-page: 79
  year: 2003
  end-page: 91
  ident: b0150
  article-title: Establishment of new preparation method for solid dispersion formulation of tacrolimus
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Ohike
– volume: 23
  start-page: 3
  year: 1997
  ident: 10.1016/j.ijpharm.2018.02.013_b0070
  article-title: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/S0169-409X(96)00423-1
  contributor:
    fullname: Lipinski
– volume: 4
  start-page: 70
  year: 2013
  ident: 10.1016/j.ijpharm.2018.02.013_b0115
  article-title: Drug-excipient behavior in polymeric amorphous solid dispersions
  publication-title: J. Excipients Food Chem.
  contributor:
    fullname: Teja
– volume: 453
  start-page: 36
  year: 2013
  ident: 10.1016/j.ijpharm.2018.02.013_b0145
  article-title: Drug precipitation inhibitors in supersaturable formulations
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2013.05.013
  contributor:
    fullname: Xu
– volume: 522
  start-page: 58
  year: 2017
  ident: 10.1016/j.ijpharm.2018.02.013_b0035
  article-title: Mathematical model to analyze the dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid interface reaction
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2017.02.050
  contributor:
    fullname: Hirai
– volume: 96
  start-page: 2686
  year: 2007
  ident: 10.1016/j.ijpharm.2018.02.013_b0025
  article-title: Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.20906
  contributor:
    fullname: Guzman
– volume: 99
  start-page: 1254
  year: 2010
  ident: 10.1016/j.ijpharm.2018.02.013_b0090
  article-title: Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.21903
  contributor:
    fullname: Murdande
– volume: 415
  start-page: 89
  year: 2011
  ident: 10.1016/j.ijpharm.2018.02.013_b0030
  article-title: Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2011.05.055
  contributor:
    fullname: Han
– volume: 3
  start-page: 130
  year: 2010
  ident: 10.1016/j.ijpharm.2018.02.013_b0005
  article-title: Preparation and evaluation of solid dispersion of terbinafine hydrochloride
  publication-title: Int. J. Pharm. Sci. Rev. Res.
  contributor:
    fullname: Arunprasad
– volume: 54
  start-page: 107
  year: 2002
  ident: 10.1016/j.ijpharm.2018.02.013_b0010
  article-title: Melt extrusion: from process to drug delivery technology
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/S0939-6411(02)00061-9
  contributor:
    fullname: Breitenbach
– volume: 286
  start-page: 538
  year: 2015
  ident: 10.1016/j.ijpharm.2018.02.013_b9000
  article-title: Pharmacological and histological examination of atorvastatin-PVP K30 solid dispersions
  publication-title: Powder Technol.
  doi: 10.1016/j.powtec.2015.08.047
  contributor:
    fullname: Jahangiri
– volume: 267
  start-page: 79
  year: 2003
  ident: 10.1016/j.ijpharm.2018.02.013_b0150
  article-title: Establishment of new preparation method for solid dispersion formulation of tacrolimus
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2003.07.010
  contributor:
    fullname: Yamashita
– volume: 1
  start-page: 386
  year: 2008
  ident: 10.1016/j.ijpharm.2018.02.013_b0015
  article-title: Preparation and characterization of solid dispersion tablet of furosemide with crospovidone
  publication-title: J. Pharm. Tech.
  contributor:
    fullname: Chaulang
– start-page: 727
  year: 2011
  ident: 10.1016/j.ijpharm.2018.02.013_b0120
  article-title: Improvement of the dissolution rate of poorly soluble drugs by solid crystal suspensions
  publication-title: Mol. Pharm.
  doi: 10.1021/mp1003493
  contributor:
    fullname: Thommes
– volume: 301
  start-page: 199
  year: 2005
  ident: 10.1016/j.ijpharm.2018.02.013_b0140
  article-title: Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2005.05.017
  contributor:
    fullname: Won
– volume: 12
  start-page: 1203
  year: 2015
  ident: 10.1016/j.ijpharm.2018.02.013_b0110
  article-title: Evolution of supersaturation of amorphous pharmaceuticals: Nonlinear rate of supersaturation generation regulated by matrix diffusion
  publication-title: Mol. Pharm.
  doi: 10.1021/mp500711c
  contributor:
    fullname: Sun
– volume: 50
  start-page: 47
  year: 2000
  ident: 10.1016/j.ijpharm.2018.02.013_b0065
  article-title: Improving drug solubility for oral delivery using solid dispersions
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/S0939-6411(00)00076-X
  contributor:
    fullname: Leuner
– volume: 85
  start-page: 799
  year: 2013
  ident: 10.1016/j.ijpharm.2018.02.013_b0130
  article-title: Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/j.ejpb.2013.09.007
  contributor:
    fullname: Vo
– volume: 7
  start-page: 1
  year: 2006
  ident: 10.1016/j.ijpharm.2018.02.013_b0085
  article-title: Enhancement of dissolution profile by solid dispersion (kneading) technique
  publication-title: AAPS PharmSciTech
  doi: 10.1208/pt070368
  contributor:
    fullname: Modi
– volume: 60
  start-page: 459
  year: 2012
  ident: 10.1016/j.ijpharm.2018.02.013_b0100
  article-title: Polymer combination increased both physical stability and oral absorption of solid dispersions containing a low glass transition temperature drug : physicochemical characterization and in vivo study
  publication-title: Chem. Pharm. Bull.
  doi: 10.1248/cpb.60.459
  contributor:
    fullname: Sakurai
– volume: 88
  start-page: 1058
  year: 1999
  ident: 10.1016/j.ijpharm.2018.02.013_b0105
  article-title: Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs
  publication-title: J. Pharm. Sci.
  doi: 10.1021/js980403l
  contributor:
    fullname: Serajuddln
– volume: 44
  start-page: 235
  year: 2000
  ident: 10.1016/j.ijpharm.2018.02.013_b0080
  article-title: Drug-like properties and the causes of poor solubility and poor permeability
  publication-title: J. Pharamacol. Toxicol. Methods
  doi: 10.1016/S1056-8719(00)00107-6
  contributor:
    fullname: Lipinski
– volume: 159
  start-page: 85
  year: 1997
  ident: 10.1016/j.ijpharm.2018.02.013_b0095
  article-title: Dissolution mechanism and rate of solid dispersion particles of nilvadipine with hydroxypropylmethylcellulose
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(97)00274-3
  contributor:
    fullname: Okimoto
– volume: 9
  start-page: e79
  year: 2012
  ident: 10.1016/j.ijpharm.2018.02.013_b0125
  article-title: The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate
  publication-title: Drug Discov. Today Technol.
  doi: 10.1016/j.ddtec.2011.10.002
  contributor:
    fullname: Van Den Mooter
– volume: 109
  start-page: 14
  year: 2016
  ident: 10.1016/j.ijpharm.2018.02.013_b0135
  article-title: Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/j.ejpb.2016.09.011
  contributor:
    fullname: Wlodarski
– volume: 52
  start-page: 244
  year: 2004
  ident: 10.1016/j.ijpharm.2018.02.013_b0040
  article-title: Application of nilvadipine solid dispersion to tablet formulation and manufacturing using crospovidone and methylcellulose as dispersion carriers
  publication-title: Chem. Pharm. Bull.
  doi: 10.1248/cpb.52.244
  contributor:
    fullname: Hirasawa
– volume: 12
  start-page: 120
  year: 2015
  ident: 10.1016/j.ijpharm.2018.02.013_b0050
  article-title: Eff ect of tablet structure on controlled release from supersaturating solid dispersions containing glyceryl behenate
  publication-title: Mol. Pharm.
  doi: 10.1021/mp500480y
  contributor:
    fullname: Keen
– volume: 445
  start-page: 108
  year: 2013
  ident: 10.1016/j.ijpharm.2018.02.013_b0055
  article-title: Supersaturatable formulations for the enhanced oral absorption of sirolimus
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2013.01.067
  contributor:
    fullname: Kim
– volume: 17
  start-page: 285
  year: 2012
  ident: 10.1016/j.ijpharm.2018.02.013_b0060
  article-title: A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept
  publication-title: Pharm. Dev. Technol.
  doi: 10.3109/10837450.2010.535826
  contributor:
    fullname: Ku
– volume: 420
  start-page: 1
  year: 2011
  ident: 10.1016/j.ijpharm.2018.02.013_b0045
  article-title: Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system : Basic approaches and practical applications
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2011.08.032
  contributor:
    fullname: Kawabata
– volume: 3
  start-page: 926
  year: 2004
  ident: 10.1016/j.ijpharm.2018.02.013_b0020
  article-title: Drugs as materials: valuing physical form in drug discovery
  publication-title: Nat. Rev.
  contributor:
    fullname: Gardner
– volume: 5
  start-page: 82
  year: 2002
  ident: 10.1016/j.ijpharm.2018.02.013_b0075
  article-title: Poor aqueous solubility – an industry wide problem in drug discovery
  publication-title: Am. Pharm. Rev.
  contributor:
    fullname: Lipinski
SSID ssj0006213
Score 2.3929706
Snippet [Display omitted] The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug...
The effects of tablet preparation and subsequent film coating with amorphous solid dispersion (ASD) particles that were composed of a drug with poor water...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 171
SubjectTerms Amorphous solid dispersion
Copovidone
Dissolution model
Melt extrusion
Polyvinylpyrrolidone
Solid–liquid interface
Title Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions
URI https://dx.doi.org/10.1016/j.ijpharm.2018.02.013
https://www.ncbi.nlm.nih.gov/pubmed/29447848
https://search.proquest.com/docview/2003037365
Volume 540
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6iFy_i2_VFBPFkd9tNm7bHZVFWRRFU8BaySQpd3LbYevDixT_uTJq6eBDBY5u0TTPTmS_NzDeEnPq-4YqlzEvBv3oIeL1UZdrLwPdoWDZnxtI13d7xyVN4_Rw9L5FxlwuDYZXO9rc23Vprd2bgZnNQ5fngwWe2sDwqJcbHoR0Owf2BTvc_FmEefOhKJMNqCXsvsngGs34-q5AgGiO8EkvdGbDf_NNv-NP6oct1suYAJB21Y9wgS6bYJGf3LQP1-zl9XCRU1ef0jN4vuKnft8hny1Zc0zKjDWZNNRRRq6vhRWWhaQ2mxMZXQ1P-MqeqlBgaTaEZwCI0V4AYkQ4UUKqmuJ_vtJd2Kf94czkvQYLlW02hObf9qvbXXL1Nni4vHscTz9Vh8BTjUeMh6V4mdaBlAtPJUj_VkQmYAiTFuOGwglNTWNZlYexPs2FslI59FXATxZJFjEu2Q5aLsjB7hMaB1gnXKvDhqkDyhHGsYGmYlCYKplGP9LvZF1VLtyG6OLSZcOISKC7hDwWIq0eSTkbih94IcAl_XXrSyVTAN4UbJbIwMDFYmhM8ewwv3yO7rbC_RzNMwzBOwmT__w8-IKt4ZON_okOy3Ly-mSOANs302OruMVkZXd1M7r4AHFX7Gg
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELYqOMAF8abLY42EOJE2qRMnOaJqUZeXkCgSN8u1HSkVTaJNOHDhwh9nxnG24oBW2mvGSRzPZOZzMvMNIWe-b7hiKfNSiK8eAl4vVZn2Mog9GrbNmbF0TXf3fPIUXj9Hzz0y7mphMK3S-f7Wp1tv7Y4M3WoOqzwfPvrMNpZHo8T8OPDDqyHiYzDqwfsyz4OPXI9k2C7h8GUZz3A-yOcVMkRjildiuTsD9l2A-g6A2kB0tUk2HIKkl-0kt0jPFNvk_KGloH67oNNlRVV9Qc_pw5Kc-m2HfLR0xTUtM9pg2VRDEba6Jl5UFprW4EtsgjWI8pcFVaXE3GgKYkCLIK4AMiIfKMBUTfGHvjNf2tX848XlogQVlq81BXFux1Xtt7l6lzxd_ZqOJ55rxOApxqPGQ9a9TOpAywSWk6V-qiMTMAVQinHDYQunZrCvy8LYn2Wj2Cgd-yrgJoolixiXbI-sFGVhDgiNA60TrlXgw1mB5Anj2MLSMClNFMyiPhl0qy-qlm9DdIloc-HUJVBdwh8JUFefJJ2OxBfDERAT_nXqaadTAS8V_imRhYGFwd6cENpjePg-2W-V_Xc2ozQM4yRMfvz_jX-Stcn07lbc_r6_OSTrKLHJQNERWWn-vJpjwDnN7MTa8Sfs_vyz
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+tablet+formulation+and+subsequent+film+coating+on+the+supersaturated+dissolution+behavior+of+amorphous+solid+dispersions&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Sakai%2C+Toshiro&rft.au=Hirai%2C+Daiki&rft.au=Kimura%2C+Shin-Ichiro&rft.au=Iwao%2C+Yasunori&rft.date=2018-04-05&rft.eissn=1873-3476&rft.volume=540&rft.issue=1-2&rft.spage=171&rft_id=info:doi/10.1016%2Fj.ijpharm.2018.02.013&rft_id=info%3Apmid%2F29447848&rft.externalDocID=29447848
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon